Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 15Terminated 2Recruiting 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1CNS 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 63Cisplatin 41Pemetrexed 39Drug Therapy 37anlotinib 23osimertinib 22Etoposide 19tislelizumab 18Paclitaxel 18Radiotherapy 17Surgical Procedures, Operative 16pembrolizumab 15toripalimab 14130-nm albumin-bound paclitaxel 14aflutinib 13Docetaxel 13Bevacizumab 12sintilimab 10Specimen Handling 10Magnetic Resonance Spectroscopy 10durvalumab 9Injections 9cemiplimab 8Radiosurgery 8Platinum 8PM 01183 8Immunotherapy 8atezolizumab 7Platinum Compounds 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × sargramostim × Thoracic × Clear all
NCT07169617 2026-06-03

Testing the SurVaxM Vaccine for Lung Cancer Prevention

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡